logo
New Study Confirms That The Oldest Rocks On Earth Are Canadians

New Study Confirms That The Oldest Rocks On Earth Are Canadians

Forbes27-06-2025
Iron-rich chert from the Nuvvuagittuq Supracrustal Belt, Québec, Canada, containing tubular and ... More filamentous microfossils.
A team of Canadian and French researchers has confirmed that Nunavik/Quebec in Northern Canada is home to the oldest known rocks on Earth, dating back over 4.16 billion years.
The rocks of the Nuvvuagittuq Greenstone Belt, a rock formation preserved in a fold of the Canada shield, are believed to be over 4.3 billion years old, forming just 200 million years after Earth formed. They include the oldest known examples of sheeted dikes and pillow basalts. Such a succession of volcanic rocks is typically found in a spreading zone of a mid oceanic ridge, forming today Earth's oceanic crust.
However, since first age estimates were published over 20 years ago, Various phases of tectonic deformation and chemical alteration makes it difficult to find pristine rock samples. There are also uncertainties involving the applied methods used at the time to date the rocks.
In a new study, researchers sampled a new section of the greenstone belt, using modern dating methods they confirmed the high age of the entire formation.
Samples were collected in 2017 near the municipality of Inukjuak, Nunavik, as part of Christian Sole's thesis, who completed a master's at the University of Ottawa in 2021. After preliminary analysis, additional work was carried out at the University of Ottawa and Carleton University, to confirm the age of the rocks.
First age estimates were based on volcanic rocks — deposited as lava flows on the bottom of an ancient ocean — chemically altered as they came into contact with water.
The researches focused on magmatic rocks, rocks crystallized before reaching the surface. Radioactive elements are trapped in the forming crystals, slowly decaying providing a natural timer for the rock's formation age.
From left: Christian Sole, Professor Hanika Rizo and Professor Jonathan O'Neil collecting rock ... More samples.
To establish the age of these rocks, the researchers combined petrology and geochemistry and applied two radiometric dating methods using different isotopes of the elements samarium and neodymium. The new dates 'gave exactly the same age,' says study author Jonathan O'Neil, University of Ottawa, in an interview to AP.
The current study shows that dikes of magmatic rocks crossing these volcanic formations are 4.16 billion years old, which confirms that the volcanic rocks must be older, and thus, that this region of the Canadian north is indeed home to the oldest known rocks on Earth.
'Understanding these rocks is going back to the very origins of our planet. This allows us to better understand how the first continents were formed and to reconstruct the environment from which life could have emerged,' concludes O'Neil.
The study,"Evidence for Hadean mafic intrusions in the Nuvvuagittuq Greenstone Belt, Canada," was published in the journal Science.
Additional material and interviews provided by the University of Ottawa.
Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

Cell Dissociation Market Size Projected to Attain USD 1,451.89 Million by 2034
Cell Dissociation Market Size Projected to Attain USD 1,451.89 Million by 2034

Yahoo

time2 hours ago

  • Yahoo

Cell Dissociation Market Size Projected to Attain USD 1,451.89 Million by 2034

The global cell dissociation market is valued at USD 461.55 million in 2025 and is projected to reach approximately USD 1,451.89 million by 2034, expanding at a CAGR of 13.58% during the forecast period. Ottawa, Aug. 20, 2025 (GLOBE NEWSWIRE) -- The global cell dissociation market size valued at USD 406.36 million in 2024, is projected to reach approximately USD 1,451.89 million by 2034, growing at a CAGR of 13.58%, according to a study by , a sister company of Precedence Research. Widespread application of cell dissociation in diagnostics, study of diseases, isolation of various cell products, etc, due to which the cell dissociation market is progressing. The Complete Study is Now Available for Immediate Access | Download the Sample Pages of this Report @ Key Takeaways North America led the market share by 38% in 2024. Asia Pacific is expected to be the fastest-growing region in the coming years. By product, the enzymatic dissociation segment dominated the cell dissociation market in 2024. By product, the non-enzymatic dissociation segment is expected to grow at the fastest CAGR during 2025-2034. By type, the tissue dissociation segment held a major share of the market in 2024. By type, the cell detachment segment is expected to witness rapid expansion in the studied years. By end-user, the pharmaceutical & biotechnology companies segment led the cell dissociation market in 2024 and is expected to grow rapidly during the forecast period. Market Overview & Potential The process in which individual cells are separated from a tissue or cell culture, usually for research or therapeutic applications, is known as cell dissociation. Primarily, they are employed in stem cell research, cancer research, tissue engineering, and drug discovery. Currently, the cell dissociation market is experiencing progression in enzymatic and mechanical methods, as well as the involvement of innovative technologies, such as portable electrical devices. Basic use of cell dissociation in the development of regenerative medicine encompasses cell isolation, manipulation, and then reintroduction into the body. Market Scope Metric Details Market Size in 2024 USD 406.36 Million Projected Market Size in 2034 USD 1451.89 Million CAGR (2025 - 2034) 13.58 % Leading Region North America Market Segmentation By Product, By Type, By End-use, By Region Top Key Players Merck KGaA, Thermo Fisher Scientific, Danaher Corp., STEMCELL Technologies, Sartorius AG, BD, Miltenyi Biotec, PAN-Biotech, HiMedia Laboratories, F. Hoffmann-La Roche Ltd., S2 Genomics, Inc. What are the Key Growth Drivers Involved in The Expansion of The Market? Around the world, the developing utilization of cell-based assays in drug discovery and development, as well as in customized medicine, is leading to an increased demand for robust cell dissociation products. The cell dissociation market is further driven by tremendous applications in the escalating demand for cell-based therapies, especially stem cell and gene therapies. Besides this, advancing research techniques, like automation and integration with omics technologies, are supporting process efficiency and further expansion of the market. You can place an order or ask any questions, please feel free to contact us at sales@ What Are the Trends Associated with the Cell Dissociation Market? In 2025, the growing emergence of numerous biotechnology and pharmaceutical industries in research and development is impacting the overall market growth. In July 2025, SPT Labtech, a global company in innovative laboratory automation, collaborated with Semarion, a University of Cambridge spin-out company from the Cavendish Laboratory, to advance automated cell-based assay workflows. In April 2025, EditCo Bio, Inc. and Promega Corporation partnered to empower the era of biologically related cell-based research, such as HiBiT, HaloTag®, and NanoLuc® technologies. In November 2024, Singleron Biotechnologies, a player in single-cell analysis solutions, made a partnership with TOMY Digital Biology Co., Ltd to enable access to Singleron's comprehensive range of single-cell analysis products and services. What Is the Major Limitation in the Market? The cell dissociation market is facing certain challenges, mainly the maintenance of high cell viability and purity after the dissociation process in the production of biopharmaceuticals and cell-based therapies. Besides this, expensive specialized enzymes, automated systems, and other reagents are creating a hindrance to developing cell dissociation technologies. Regional Analysis Become a valued research partner with us - Why did North America Dominate the Cell Dissociation Market in 2024? The market is propelled by immense investments in life sciences research in this region, impacting market development, primarily in the US. Moreover, this region possesses advanced biotechnology and a pharmaceutical industry, and a strong healthcare infrastructure. Along with this, North America's emphasis on the development of precision medicine, 3D cell culture models, and advanced therapies like gene editing is expanding demand for more sophisticated and effective cell dissociation solutions. For instance, In March 2025, RoslinCT and Ayrmid Pharma made a strategic partnership for the production of Omisirge®, a treatment for hematologic malignancies commercialized in the United States by Gamida Cell, a subsidiary of Ayrmid Pharma. In October 2024, FibroBiologics Inc., a clinical-stage biotechnology company, and Charles River Laboratories, a leading drug discovery, development, testing, and manufacturing solutions provider, signed an agreement to develop and manufacture FibroBiologics' therapeutic master cell bank, working cell bank, and fibroblast-based spheroids product, CYWC628. What Made the Asia Pacific Significantly Grow in the Market in 2024? During 2025-2034, the Asia Pacific will expand at the fastest CAGR in the cell dissociation market. Combined factors are impacting the overall market expansion in the ASAP countries, such as China. Japan, India, and South Korea. An expanding healthcare system, with increased focus on R&D, especially in regenerative medicine and stem cell research, is widely involved in the market expansion. Apart from this, ongoing government initiatives to boost the biotechnology domain and accelerate the pipeline in clinical research activities are also propelling the adoption of innovative technologies. For this market, In August 2025, CytoNiche Biotech, a leader in 3D cell production technology, inaugurated its 3D FloTrix™ Experience Hub in Singapore. In July 2025, NKGen Biotech, Inc., a clinical-stage biotechnology company, and Japan-based HekaBio K.K., partnered to expand the regulatory, manufacturing, and commercial development of NKGen's autologous NK cell therapy, troculeucel, in Japan following HekaBio's recently announced investment in common equity of NKGen. Get the latest insights on life science industry segmentation with our Annual Membership: Segmental Insights By product analysis How did the Enzymatic Dissociation Segment Lead the Market in 2024? In 2024, the enzymatic dissociation segment registered dominance in the cell dissociation market. This type of product can give higher cell yield with broader effectiveness at extracting cells from dense or complex tissues as compared to other mechanical methods. Moreover, this approach offers its flexibility in different downstream applications, like flow cytometry, cell sorting, and in vitro assays. Alongside its wide-range utilization in the development of numerous cell-based therapies and its ability to minimize the amount of fibrous connective tissue present in the cell suspension, it boosts further cell viability and downstream analysis in the market. However, the non-enzymatic dissociation segment is predicted to experience rapid growth in the studied years. This product type has several advantages, like it can preserve cell surface proteins, which is vital for downstream assays. Furthermore, non-enzymatic dissociation is favourable for sensitive cells. Also, they are obtained without animal-derived components, making them adaptable for various cell-based therapies is driving overall segment and market expansion. Whereas, non-enzymatic dissociation is greatly employed in isolating and expanding MSCs while protecting their key functional properties. By type analysis Which Type Held the Largest Share of the Cell Dissociation Market in 2024? The tissue dissociation segment dominated the market with a major share in 2024. The segment is driven by rising research in oncology, chronic conditions, and breakthroughs in cell-based therapies. This type mainly contributes to the separation of cells from a tissue sample to create a single-cell suspension, which is further necessary for isolating cells for therapeutic use, research, and diagnostics. Moreover, the cell detachment segment is estimated to grow fastest during 2025-2034. The significance of cell detachments in cell culture, particularly in culturing adherent cells, is increasingly applied in many research and therapeutic applications. Along with this, a rise in demand for monoclonal antibodies in biopharmaceutical and pharmaceutical industries is immensely dependent on cell culture and, consequently, cell detachment techniques. Eventually, they encompass mechanical detachment (scraping or shaking) and physical methods, such as thermal, light, or magnetic manipulation, which can be selected based on the cell type, culture conditions, and downstream applications. By end-user analysis What Made the Pharmaceutical & Biotechnology Companies Segment Dominate in the Market in 2024? The pharmaceutical & biotechnology companies segment was dominant in the cell dissociation market in 2024 and will expand at the fastest CAGR. Widespread use of cell dissociation is seen in these companies, particularly in vaccine development, production of diverse biopharmaceutical products, and cancer research. Additionally, the segment is fueled by the adoption of cell dissociation in drug discovery and development, allowing the generation of single-cell suspensions, which are essential for high-throughput screening of possible drug candidates. The utilization of the single-cell RNA sequencing (scRNA-seq) technique relies on cell dissociation for the analysis of gene expression profiles in individual cells, demonstrating significant insights into drug responses and cellular heterogeneity. Recent Developments in the Cell Dissociation Market In July 2025, AscellaHealth, a leading partner delivering customizable solutions to support the specialty pharmaceutical industry, partnered with Abeona Therapeutics Inc. for pre- and post-launch commercialization of ZEVASKYN™, an FDA-approved cell-based gene therapy. In April 2025, Singleron Biotechnologies launched PythoN i, an advanced tissue having in nuclei extraction and tissue homogenization functions to its tissue processing system. In March 2025, Sphere Bio, a major provider of innovative picodroplet-based microfluidics solutions for functional single-cell analysis and isolation, introduced the Cyto-Cellect® Human IgG Kappa and Viability Assay Kit, the first multiplexed assay developed specifically for the Company's new Cyto-Mine® Chroma platform. In April 2024, Kuraray Co., Ltd. developed PVA (Polyvinyl Alcohol) hydrogel microcarriers for cell cultures used in regenerative medicine. Browse More Insights of Towards Healthcare: The global single-cell sequencing market was valued at US$ 1.63 billion in 2024 and is anticipated to rise to US$ 1.88 billion by 2025. By 2034, the market is projected to exceed US$ 6.65 billion, advancing at a CAGR of 15.05%. The global cellular immunotherapy market reached US$ 11.33 billion in 2024 and is expected to grow to US$ 13.87 billion in 2025, before surging to nearly US$ 85.78 billion by 2034, expanding at a robust CAGR of 22.45% during the forecast period. The global cell and gene therapy clinical trials market was valued at US$ 10.8 billion in 2024, grew to US$ 12.47 billion in 2025, and is projected to achieve US$ 45.31 billion by 2034, registering a CAGR of 15.43% from 2025 to 2034. The global cell-based assays market stood at US$ 17.29 billion in 2024 and is forecast to increase to US$ 18.82 billion in 2025. By 2034, it is anticipated to surpass US$ 39.92 billion, advancing at a CAGR of 8.84%. The global biopharmaceutical contract manufacturing market was calculated at US$ 40.14 billion in 2024, expanded to US$ 44.61 billion in 2025, and is projected to reach approximately US$ 115.65 billion by 2034, growing at a CAGR of 11.14% between 2025 and 2034. The global cell and gene solutions market is on a strong growth trajectory, with revenue expected to scale significantly over the forecast years from 2025 to 2034, potentially reaching into the hundreds of millions. The global cell-based immunotherapies market was valued at US$ 4.59 billion in 2024, is set to grow to US$ 5.28 billion in 2025, and is projected to generate US$ 18.62 billion by 2034, expanding at a CAGR of 15.02% throughout the forecast period. The global cell banking outsourcing market reached US$ 14.37 billion in 2024, expanded to US$ 16.72 billion in 2025, and is forecast to hit US$ 63.49 billion by 2034, growing at a strong CAGR of 16.37%. The global stem cell banking market was valued at US$ 7.85 billion in 2024, grew to US$ 9.12 billion in 2025, and is projected to climb to US$ 35.12 billion by 2034, advancing at a CAGR of 16.14% between 2025 and 2034. The global host cell protein testing market stood at US$ 2.37 billion in 2024, increased to US$ 2.56 billion in 2025, and is projected to cross US$ 5.19 billion by 2034, expanding at a CAGR of 8.17%. The global stem cell assay market was valued at US$ 2.68 billion in 2024, grew to US$ 3.15 billion in 2025, and is expected to achieve US$ 13.5 billion by 2034, rising at a significant CAGR of 17.55%. The global live cell imaging market reached US$ 2.92 billion in 2024, expanded to US$ 3.16 billion in 2025, and is anticipated to generate US$ 6.49 billion by 2034, progressing at a CAGR of 8.34%. The global immortalized cell line market was valued at US$ 4.55 billion in 2024, increased to US$ 4.85 billion in 2025, and is projected to attain US$ 8.68 billion by 2034, advancing at a CAGR of 6.71%. The global cell viability assays market stood at US$ 1.89 billion in 2024, grew to US$ 2.05 billion in 2025, and is projected to reach US$ 4.24 billion by 2034, expanding at a CAGR of 8.54%. The global stem cell reconstructive market was valued at US$ 1.56 billion in 2024, is forecast to grow to US$ 1.88 billion in 2025, and is expected to achieve US$ 10.32 billion by 2034, advancing at an impressive CAGR of 20.81%. Cell Dissociation Market Key Players Merck KGaA Thermo Fisher Scientific Danaher Corp. STEMCELL Technologies Sartorius AG BD Miltenyi Biotec PAN-Biotech HiMedia Laboratories F. Hoffmann-La Roche Ltd. S2 Genomics, Inc. Segments Covered in The Report By Product Enzymatic Dissociation Trypsin Collagenase Elastase Papain Hyaluronidase DNase Others Non-enzymatic dissociation Instruments & Accessories By Type Tissue Dissociation Cell Detachment By End-use Pharmaceutical & Biotechnology Companies Research & Academic Institutes By Region North America U.S. Canada Mexico Europe Germany UK Spain Italy France Denmark Norway Sweden Asia Pacific Japan China India Australia Thailand South Korea Latin America Brazil Argentina MEA South Africa Saudi Arabia UAE Kuwait Access our exclusive, data-rich dashboard dedicated to the healthcare market - built specifically for decision-makers, strategists, and industry leaders. The dashboard features comprehensive statistical data, segment-wise market breakdowns, regional performance shares, detailed company profiles, annual updates, and much more. From market sizing to competitive intelligence, this powerful tool is one-stop solution to your gateway. Access the Dashboard: Immediate Delivery Available | Buy This Premium Research @ About Us Towards Healthcare is a leading global provider of technological solutions, clinical research services, and advanced analytics, with a strong emphasis on life science research. Dedicated to advancing innovation in the life sciences sector, we build strategic partnerships that generate actionable insights and transformative breakthroughs. As a global strategy consulting firm, we empower life science leaders to gain a competitive edge, drive research excellence, and accelerate sustainable growth. You can place an order or ask any questions, please feel free to contact us at sales@ Europe Region: +44 778 256 0738 North America Region: +1 8044 4193 44 Web: Our Trusted Data Partners Precedence Research | Statifacts | Towards Packaging | Towards Automotive | Towards Food and Beverages | Towards Chemical and Materials | Towards Consumer Goods | Towards Dental | Towards EV Solutions | Nova One Advisor | Healthcare Webwire | Packaging Webwire | Automotive Webwire Find us on social platforms: LinkedIn | Twitter | Instagram | Medium | PinterestError in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data

Single-Use Bioreactors Market Size to Envision USD 22.46 Billion by 2034
Single-Use Bioreactors Market Size to Envision USD 22.46 Billion by 2034

Yahoo

time3 hours ago

  • Yahoo

Single-Use Bioreactors Market Size to Envision USD 22.46 Billion by 2034

The global single-use bioreactors market is valued at USD 5.38 billion in 2025 and is projected to expand to approximately USD 22.46 billion by 2034, advancing at a CAGR of 17.21% during the forecast period. Ottawa, Aug. 20, 2025 (GLOBE NEWSWIRE) -- The global single-use bioreactors market size was valued at USD 4.59 billion in 2024 and is projected to reach approximately USD 22.46 billion by 2034, growing at a CAGR of 17.21%, according to a study by Towards Healthcare, a sister company of Precedence Research. The accelerating demand for cell therapies and tailored medicine is contributing to the growth of the single-use bioreactors market. The Complete Study is Now Available for Immediate Access | Download the Sample Pages of this Report @ Key Takeaways North America was dominant in the market share by 35% in 2024. Asia Pacific is expected to grow at the fastest CAGR during 2025-2034. By product, the single-use bioreactor systems segment led the market in 2024. By product, the single-use media bags segment is expected to witness significant expansion in the studied years. By type, the stirred tank SUBs segment dominated the market in 2024 and is expected to grow rapidly in the upcoming years. By cell type, the mammalian cells segment registered dominance in the single-use bioreactors market in 2024. By cell type, the bacterial cells segment is expected to grow at a notable CAGR in the predicted timeframe. By molecule type, the vaccines segment captured the largest share of the market in 2024. By molecule type, the gene modified cells segment is expected to register the fastest expansion during the forecast period. By application, the research and development (R&D) or process development segment led the market in 2024. By application, the bioproduction segment is expected to be the fastest-growing during 2025-2034. By usage, the lab-scale production segment led the single-use bioreactors market in 2024. By usage, the large-scale production segment is expected to grow significantly in the projected period. By end-use, the CMOs & CROs segment held a major revenue share of the market in 2024. By end-use, the pharmaceutical and biopharmaceutical companies segment is expected to register significant growth during 2025-2034. Market Overview & Potential Primarily, single-use bioreactors are disposable, pre-sterilized bioreactors established for cell culture and microbial fermentation. Furthermore, providing benefits, including minimized contamination risk, minimal capital expenditure, and quicker turnaround times compared to conventional stainless steel systems. The single-use bioreactors market possesses numerous applications in the biopharmaceutical industry for the manufacturing of different biologics like vaccines, monoclonal antibodies, and recombinant proteins. Besides this, in 2025, the market will boost automation, scalability, and process control, with the launch of novel models and features. Report Scope Metric Details Market Size in 2024 USD 4.59 Billion Projected Market Size in 2034 USD 22.46 Billion CAGR (2025 - 2034) 17.21 % Leading Region North America Market Segmentation By Product, By Type, By Type of Cell, By Molecule Type, By Application, By Usage Type, By End-use, By Region Top Key Players Sartorius Stedim Biotech, Thermo Fisher Scientific, Danaher, Merck KgaA, Celltainer Biotech BV, Getinge AB, Eppendorf AG, Cellexus, PBS Biotech Inc., Distek Inc., ABEC, Able Corporation & Biott Corporation, G&G Technologies Inc., Solida Biotech GmbH, Satake Chemical Equipment Mfg., Ltd., Stobbe Pharma GmbH, bbi-biotech GmbH You can place an order or ask any questions, please feel free to contact us at sales@ What are the Key Drivers in the Developing Market? Across the single-use bioreactors market, several factors contribute to the expansion, such as it has affordability and enhanced efficiency. Other drivers involved in the comprehensive development of the market are the growing innovations in bioreactor design and the emergence of large-scale single-use bioreactors. Apart from this, the rising demand for diverse biologics, like monoclonal antibodies, vaccines, and cell & gene therapies, is fueling the adoption of single-use bioreactors. What are the Trends in the Single-Use Bioreactors Market? The market is experiencing major growth due to accelerating pharmaceutical R&D expenses and the movement towards sustainable manufacturing practices. In March 2025, the collaboration, named Project Nexus, secured £1.4 million in funding from Innovate UK's Sustainable Medicines Manufacturing Innovation, focused on cultivating new sustainable materials customized for single-use bioprocessing equipment, like bioreactors. In June 2024, AGC Biologics expanded its single-use bioreactor capacity with progression at the Denmark site. What Is the Arising Challenge in the Market? In the single-use bioreactors market, challenges are developing hurdles in its expansion, such as a consistent requirement for single-use components like bags, filters, etc. accelerate the expenses. Besides this, issues regarding the consistency and reliability of performance from one single-use bag to another, possibly impacting batch-to-batch reproducibility, are another barrier in numerous pharmaceutical companies. Become a valued research partner with us - Regional Analysis Why Did North America Dominate the Market in 2024? In 2024, North America captured the largest revenue share of 35% in the single-use bioreactors market. Due to affordability and rapid turnaround times, reduced cleaning and validation requirements are assisting in the adoption of single-use bioreactors in this region. Along with this, expanding demand and production for biologics, especially monoclonal antibodies, vaccines, and cell and gene therapies, are propelling in the leading pharmaceutical companies of this region. This further supports a rise in efficiency and scalability scalable manufacturing solutions. For instance, In August 2025, Cytiva collaborated with Culture Biosciences, which specializes in cloud-connected bioreactor technology, to support both hardware commercialization and technology development. In January 2025, Sartorius and McMaster University opened a Canadian bioprocessing hub of about a 1,600 square-foot bioprocess research facility in Hamilton, Ontario, about 38 miles south of Toronto. In October 2024, Recipharm and Exela collaborated to expand US sterile injectable production. How is Asia Pacific Growing in Single-use Bioreactors Market? During 2025-2034, the Asia Pacific is anticipated to expand at the fastest CAGR in the single-use bioreactors market. In the ASAP countries, such as China and India, are actively involved in the investment in biopharmaceutical research and development activities, which are further assisting in the emergence of the single-use bioreactors in various bioprocessing. Alongside, Contract Manufacturing Organizations (CMOs) of ASAP are widely adopting single-use bioreactors to enable feasible manufacturing solutions and minimal cross-contamination risks. Adaptable government policies and incentives focused on the development of the biotechnology sector in ASAP countries are further accelerating the market growth. For instance, In June 2025, Hyderabad-based Biological E Limited (BE) partnered with China's Jiangsu Recbio Technology Company Limited to manufacture and distribute a 9-valent Human Papillomavirus (HPV9) vaccine. Get the latest insights on life science industry segmentation with our Annual Membership: Segmental Insights By product analysis How did the Single-Use Bioreactor Systems Dominate the Market in 2024? The single-use bioreactor systems segment registered dominance in the single-use bioreactors market in 2024. The segment is driven by the growing production of biologics and biosimilars. Moreover, many advantages of this system, such as its flexibility, scalability, affordability, and minimal chances of cross-contamination, are influencing overall market growth. Along with this, single-use bioreactors use less water and energy for their operation. On the other hand, the single-use media bags segment is estimated to grow significantly during 2025-2034. These bags are broadly employed in the preparation and storage of sterile media and buffers, which are necessary for cell proliferation and other bioprocessing stages. Also, they are a feasible and effective approach to manage crucial fluids, with the elimination of requirement for need for conventional stainless steel tanks and associated cleaning processes. Along with this, single-use bags are employed in conjunction with chromatography systems in the separation and purification of target molecules. By type analysis Why did the Stirred Tank Subs Segment Lead the Market in 2024? The stirred tank SUBs segment was dominant in the market in 2024 and is estimated to grow at a rapid CAGR in the single-use bioreactors market. This type of bioreactor possesses superior mixing and aeration capabilities, which are important for high-density cell cultures. Involvement of this type of bioreactor in biopharmaceutical manufacturing of monoclonal antibody (MAb) therapies and other biological products is driving the overall segment's growth. Apart from this, stirred tank SUBs have a vital significance in scale-up processes from R&D to production, allied with their inexpensive and minimized risk of contamination. By cell type analysis Which Cell Type Led the Single-Use Bioreactors Market in 2024? The mammalian cells segment held a dominant revenue share of the market in 2024. These types of cells are widely used in the production of complex biologics, including monoclonal antibodies and therapeutic proteins, which are in increasing demand for advanced therapies. This ultimately enhances the adoption of single-use bioreactors. Also, mammalian cells play a crucial role in expressing functional enzymes for therapeutic applications, including enzyme replacement therapies. Eventually, mammalian cells like BHK-21, Vero, and MDCK are applied in the production of viral vaccines for both human and veterinary applications. Whereas, the bacterial cells segment is estimated to witness significant growth during 2025-2034. Widespread applications of bacterial cells in the biopharmaceutical production, like recombinant protein production, are fueling demand for single-use bioreactors to achieve an essential target. In the case of recombinant protein production, bacterial expression systems such as E. coli are incorporated to accelerate the development of insulin and other therapeutic proteins. Derivatives of bacterial antigens are immensely used in vaccine development. By molecule type analysis What Made the Vaccines Segment Dominant in the Market in 2024? In the single-use bioreactors market, the vaccines segment accounted for a major share in 2024. Varied aspects of single-use bioreactors in vaccine development mainly comprise their rapid product development cycles and quicker turnaround times. Moreover, they have decreased risk of cross-contamination among batches, which ultimately ensures greater product purity and consistency, which is impacting as an important aspect in vaccine production. One of the significant factors, such as raising investments in the pharmaceutical R&D sector, is boosting the adoption of single-use bioreactors for novel vaccine development. However, the gene modified cells segment is anticipated to expand rapidly during 2025-2034. The segment is propelled by a huge demand for cell and gene therapies, which are widely used in oncology and rare genetic disorders. Alongside, single-use bioreactors encompass properties to control specific parameters precisely, such as temperature, pH, and oxygen levels, ensuring optimal expansion conditions for gene-modified cells. Examples like wave bioreactors are applied in a rocking motion to evolve a wave-like movement in the culture bag, ensuring efficient mixing and gas exchange. By application analysis Which Application Dominated the Single-Use Bioreactors Market in 2024? The research and development (R&D) or process development segment held the biggest revenue share of the market in 2024. Across the market, the segment consists of broader utilization of single-use bioreactors in R&D to standardize conditions for scaling up production and confirm continuous effectiveness from lab to industrial level. Apart from this, these bioreactors are favourable for small-scale R&D, particularly in testing new cell lines and media formulation. As well as phenomenal advances in single-use bioreactor technology, like optimized mixing and oxygen transfer, are boosting their adoption in R&D. And, the bioproduction segment is predicted to register rapid expansion in the respective market. The feasibility of single-use bioreactors during the delivery, with maintaining their sterility and ready for installation features are streamlines the bioproduction setup process. Other properties of these bioreactors are impacting bioproduction, including the usage of polymers and plastics that must be compatible with cell culture, which are sterilized by the application of gamma irradiation to avoid pH fluctuations. This expansion of bioproduction will also comprise non-invasive sensors that can monitor temperature, dissolved oxygen, and pH, further minimizing the risk of contamination. By usage analysis Why did the Lab-scale Production Segment Hold a Major Share of the Market in 2024? In the single-use bioreactors market, the lab-scale production segment was dominant in 2024. Currently, the increasing focus on the development of precision medicine, which necessitates smaller batch sizes and customized therapies, is immensely influencing this segment expansion. Additionally, the single-use bioreactors greatly support the transformation and optimization of cell lines for different biopharmaceutical applications. In case of lab-scale production, a wide range of profitable approaches involve using these bioreactors, like in research, preclinical studies, or clinical trials. On the other hand, the large-scale production segment is predicted to expand at a notable CAGR during 2025-2034. Various Contract Development and Manufacturing Organizations (CDMOs) and small and medium-sized enterprises (SMEs) are broadly adopting single-use bioreactors due to their cost-effectiveness and minimal operational spending. Furthermore, consistent advances in single-use technologies, like larger-scale bioreactors and improved mixing and oxygen transfer capabilities, are propelling overall market development. Adoption of highly sophisticated sensor technologies and automation is further integrated into single-use systems to expand process monitoring and control, with allowance of process analytical technology (PAT). By end-use analysis How did the CMOs & CROs Segment Dominate the Market in 2024? The CMOs & CROs segment led the single-use bioreactors market in 2024. Primarily, contributing factors are a rise in outsourcing and the advantages of single-use techniques, including their flexibility, inexpensiveness, and accelerated timelines in biopharmaceutical development and manufacturing. However, CMOs and CROs are leveraging these approaches for strong biopharmaceutical production, especially for a variety of product portfolios and quick campaign turnarounds. The pharmaceutical and biopharmaceutical companies segment is anticipated to register notable growth in the future. Many global providers of single-use technology, particularly single-use bioreactors, are also highly enabling optimization of solutions for mammalian cell culture, high cell-density processes, and microcarrier-based processes. Whereas some companies are offering scientific instrumentation, reagents, consumables, and software, with the inclusion of single-use bioreactors for numerous applications. In several companies, single-use bioreactors are suitable for biopharmaceutical production, mainly for the production of monoclonal antibodies and other biologics. Recent Developments In February 2025, US-based Sunflower Therapeutics announced its foremost distribution agreement with PharmNXT Biotech, an Indian bioprocessing company, to launch its Daisy Petal Perfusion Bioreactor System in Asia, a crucial step in the company's ongoing product commercialization. In September 2024, Culture Biosciences, a developer of automated bioprocess development tools, collaborated with Google Cloud, which will integrate Culture's real-time data monitoring and cloud-connected bioreactors with Gemini AI and other advanced data tools designed by Google. Browse More Insights of Towards Healthcare: The global single cell sequencing market was valued at US$ 1.63 billion in 2024 and is projected to reach US$ 1.88 billion in 2025. By 2034, the market is anticipated to surpass US$ 6.65 billion, expanding at a steady CAGR of 15.05%. The global single-use assemblies market stood at USD 13.25 billion in 2024 and is forecast to grow to USD 15.39 billion in 2025. It is expected to achieve nearly USD 58.44 billion by 2034, progressing at a CAGR of 16.15% between 2025 and 2034. The global single-cell biotherapeutics market is witnessing an upward growth trend and is expected to generate significant revenue, potentially scaling into the hundreds of millions over the forecast period of 2025–2034. The global single-use downstream bioprocessing market was valued at USD 1.57 billion in 2024, rising to USD 1.79 billion in 2025, and is estimated to reach around USD 5.9 billion by 2034, advancing at a CAGR of 14.24% during 2025–2034. The global single-use sensors market was worth USD 0.47 billion in 2024 and is projected to increase to USD 0.54 billion in 2025. By 2034, it is expected to climb to about USD 1.86 billion, recording a CAGR of 15.04% between 2025 and 2034. The global single cell analysis market reached USD 5.19 billion in 2024 and is expected to grow to USD 6.16 billion in 2025. By 2034, the market is forecast to attain USD 29.15 billion, expanding rapidly at a CAGR of 18.74% over the period. The global single nucleotide polymorphism (SNP) genotyping market was valued at USD 6.48 billion in 2024, increasing to USD 7.24 billion in 2025, and is projected to reach nearly USD 19.48 billion by 2034, with a CAGR of 11.7% between 2025 and 2034. The global single-cell omics market accounted for US$ 1.94 billion in 2024, growing to US$ 2.35 billion in 2025. By 2034, it is forecast to generate around US$ 12.05 billion, advancing at a CAGR of 16.14%. The global single-use pump market was valued at US$ 451.81 million in 2023 and is projected to reach approximately US$ 2.13 billion by 2034, expanding at a CAGR of 15.95% during 2024–2034. The global single-use bioprocessing market is anticipated to grow from USD 30.77 billion in 2025 to nearly USD 112.2 billion by 2034, registering a CAGR of 15.46% over the forecast period. Single-Use Bioreactors Market Key Players Sartorius Stedim Biotech Thermo Fisher Scientific Danaher Merck KgaA Celltainer Biotech BV Getinge AB Eppendorf AG Cellexus PBS Biotech Inc. Distek Inc. ABEC Able Corporation & Biott Corporation G&G Technologies Inc. Solida Biotech GmbH Satake Chemical Equipment Mfg., Ltd. Stobbe Pharma GmbH bbi-biotech GmbH Segments Covered in The Report By Product Single-use Bioreactor Systems Up to 10L 11-100L 101-500L 501-1500L Above 1500L Single-use media bags 2D Bags 3D Bags Others Single-use Filtration Assemblies Other Products By Type Stirred-tank SUBs Wave-induced SUBs Bubble-column SUBs Other SUBs By Type of Cell Mammalian Cells Bacterial Cells Yeast Cells Other Cells By Molecule Type Monoclonal Antibodies Vaccines Gene Modified Cells Stem Cells Other Molecules By Application Research and Development (R&D) or Process Development Bioproduction By Usage Type Lab-scale Production Pilot-scale Production Large-scale Production By End-use Pharmaceutical & Biopharmaceutical Companies CROs & CMOs Academic & Research Institutes By Region North America US Canada Asia Pacific China Japan India South Korea Thailand Europe Germany UK France Italy Spain Sweden Denmark Norway Latin America Brazil Mexico Argentina Middle East and Africa (MEA) South Africa UAE Saudi Arabia Kuwait Immediate Delivery Available | Buy This Premium Research @ Access our exclusive, data-rich dashboard dedicated to the healthcare market - built specifically for decision-makers, strategists, and industry leaders. The dashboard features comprehensive statistical data, segment-wise market breakdowns, regional performance shares, detailed company profiles, annual updates, and much more. From market sizing to competitive intelligence, this powerful tool is one-stop solution to your gateway. Access the Dashboard: About Us Towards Healthcare is a leading global provider of technological solutions, clinical research services, and advanced analytics, with a strong emphasis on life science research. Dedicated to advancing innovation in the life sciences sector, we build strategic partnerships that generate actionable insights and transformative breakthroughs. As a global strategy consulting firm, we empower life science leaders to gain a competitive edge, drive research excellence, and accelerate sustainable growth. You can place an order or ask any questions, please feel free to contact us at sales@ Europe Region: +44 778 256 0738 North America Region: +1 8044 4193 44 Web: Our Trusted Data Partners Precedence Research | Statifacts | Towards Packaging | Towards Automotive | Towards Food and Beverages | Towards Chemical and Materials | Towards Consumer Goods | Towards Dental | Towards EV Solutions | Nova One Advisor | Healthcare Webwire | Packaging Webwire | Automotive Webwire Find us on social platforms: LinkedIn | Twitter | Instagram | Medium | Pinterest

Breastfeeding could help prevent early puberty in girls and boys, South Korean study finds
Breastfeeding could help prevent early puberty in girls and boys, South Korean study finds

Yahoo

time14 hours ago

  • Yahoo

Breastfeeding could help prevent early puberty in girls and boys, South Korean study finds

Girls and boys who were exclusively breastfed during their first four to six months showed a reduced risk of early puberty, according to a large new study from South Korea that Canadian doctors say could apply here. The study, published in Monday's issue of JAMA Network Open, looked back at the diets and development of more than 300,000 children from 2007 to 2020, based on data from checkups at four to six months of age and before six years. Worldwide, puberty has increasingly begun earlier in kids. Called "central precocious puberty," it's linked to an increased risk of health problems in adulthood, like heart disease, cancer and diabetes, as well as mental health issues like depression and anxiety. The researchers believe that kids who are exclusively breastfed are less likely to develop childhood obesity, a major predisposing factor of early puberty. However, experts note that many mothers face challenges in breastfeeding, which they say should be addressed on a structural level. "The take-home message should be, for parents or to-be parents, that breastfeeding has multiple beneficial health effects for their children," said Dr. Sonia Anand, associate vice-president of global health at McMaster University, who was not involved in the study. "And the second message is it is not always easy to do." Long-term benefits of breastfeeding About 46 per cent of the babies in the South Korean study were exclusively breastfed, more than a third had formula and nearly 20 per cent had both. "The idea is that breastfed kids are less likely to have extra weight and that's the mechanism whereby they're more protected from developing early puberty," said Dr. Kaberi Dasgupta, a professor of medicine and physician scientist at the McGill University Health Centre, who also was not involved in the study. Boys who were fed just formula had a 16 per cent increased risk of early puberty compared with their peers who were only fed breast milk, the researchers found. For exclusively formula-fed girls, the association jumped to 60 per cent. For mixed-fed boys, it was 14 per cent higher, compared with 45 per cent for girls. The researchers noted some caveats to their study. The participants self-reported how long they breastfed their children, for example. It also couldn't include genetic factors like maternal age of puberty. The early part of life is a key time, as that's when a lot of disease risk is set, wrote doctors Lin Yang and Shengxu Li. Though they weren't involved in the study, they wrote an accompanying journal commentary. "Disease starts early, so should its prevention," they said. Dasgupta says there's no reason to think the findings would be different in Canada. Preventing early puberty can also help kids in other ways, she adds. "The earlier your puberty, the shorter you may become," she said. "There's also the stigma around having early signs of being an adult when you're still a kid. Other kids may tease you." Supporting mothers instead of shaming Yang and the researchers say that instead of putting pressure on new moms, a society-wide approach is important. That includes stronger parental leave policies, workplace accommodations like a private space to breastfeed and lactation support services. "I think policy support, raised awareness, as well as creating the environment for women to be able to [breastfeed] is very important," Yang told CBC News. Sleep patterns, physical activity levels and screen time could also be increasing childhood obesity and early puberty rates, Yang and Li wrote in their commentary, as well as environmental pollutants like endocrine disruptors, though she acknowledged there isn't good data on that. In Canada, about 91 per cent of parents start out breastfeeding. About 38 per cent of parents breastfed exclusively for at least six months, Statistics Canada reported in 2024. Of those who stopped before six months, reasons included not having enough breast milk, finding breastfeeding difficult and the child weaning themself off of it. "I think the wrong takeaway and the wrong approach is to shame mothers who try to breastfeed but can't continue," Anand said. Breastfeeding is one factor among many that can influence weight gain in kids. Lifestyle choices like limiting fast food and cooking with more vegetables and lean proteins can also help prevent childhood obesity, doctors say. While the South Korean study doesn't prove that formula feeding causes early puberty, the researchers had a robust data set and the associations are plausible, she said. Anand's own research demonstrated early breastfeeding and for at least six months was associated with lower levels of excess body fat in children at age three. She says she'd like to see other large studies show similar findings to the South Korean to nail down cause and effect. Studies looking at how genes are tied to precocious puberty could also help, she said.

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into a world of global content with local flavor? Download Daily8 app today from your preferred app store and start exploring.
app-storeplay-store